AstraZeneca chief quits CSL board over $50 billion acquisition
AstraZeneca’s Pascal Soriot will depart the CSL board next month to prevent potential conflicts of interest after his company bought a US immunology startup.
from Sydney Morning Herald - Latest News Read More
No comments:
Post a Comment
Thank You for sharing your views. I hope you like the arts posted.
No comments:
Post a Comment
Thank You for sharing your views. I hope you like the arts posted.